Sarepta Therapeutics, Inc.

Equities

SRPT

US8036071004

Market Closed - Nasdaq Other stock markets 01:30:00 14/03/2026 am IST			5-day change	1st Jan Change
16.40 ^USD	-3.76%		-1.86%	-23.79%

04/03	NervGen Pharma Corp. Announces Executive Changes	CI
04/03	Sarepta Therapeutics, Inc. Presents at TD Cowen 46th Annual Health Care Conference, Mar-03-2026 01:50 PM

Transcript : Sarepta Therapeutics, Inc. Presents at BofA Securities 2025 Healthcare Conference, May-14-2025 08

Published on 05/15/2025 at 02:00 am IST - Modified on 05/14/2025 at 09:10 pm IST

S&P Capital IQ

Presenter Speech
Tazeen Ahmad (Analysts)

And here at the Bank of America Healthcare Conference, I'm Tazeen Ahmad. I'm one of the senior SMid biotech analysts at the firm. It's my pleasure to have our

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Latest news about Sarepta Therapeutics, Inc.

04/03	NervGen Pharma Corp. Announces Executive Changes	CI
04/03	Sarepta Therapeutics, Inc. Presents at TD Cowen 46th Annual Health Care Conference, Mar-03-2026 01:50 PM
02/03	Pfizer CEO flags concerns with US FDA's vaccine leadership	RE
02/03	Wedbush Adjusts Sarepta Therapeutics PT to $29 From $34, Maintains Outperform Rating	MT
26/02	Sarepta Therapeutics CEO Ingram to retire by year end	RE
26/02	Sarepta Therapeutics, Inc., Q4 2025 Earnings Call, Feb 25, 2026
26/02	Douglas Ingram Plans to Retire as Chief Executive Officer of Sarepta Therapeutics, Inc	CI
26/02	Earnings Flash (SRPT) Sarepta Therapeutics, Inc. Reports Q4 Revenue $442.9M, vs. FactSet Est of $369.6M	MT
26/02	Earnings Flash (SRPT) Sarepta Therapeutics, Inc. Posts Q4 Adjusted Loss $3.58 per Share	MT
26/02	Sarepta Therapeutics announces fourth quarter and full-year 2025 financial results	RE
26/02	Sarepta Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025	CI
24/02	Sarepta Therapeutics, Inc. Announces Commercial Launch of ELEVIDYS in Japan	CI
24/02	Sarepta Therapeutics Says Elevidys Available in Japan for Duchenne Muscular Dystrophy	MT
24/02	Sarepta Therapeutics announces commercial launch of Elevidys in Japan	RE
21/02	Regenxbio Wins Appeal in Patent Dispute With Sarepta Therapeutics	MT